News Feed

MPN News

MPN rss feedThe MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources.  Just click on the red hyperlink to pull up the complete news item.

Make PV Reporter your “starting point” for all MPN related news.

 

Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in the United States. Some cancers are well-known, but others are quite rare. Polycythemia Vera (PV) is part of a group of rare blood cancers called [...]
Fri, Apr 28, 2017, Continue reading at the source
The U.S. Food and Drug Administration (FDA) has granted marketing approval to the ipsogen JAK2 RGQ PCR Kit – the first FDA-authorized in vitro test for the evaluation of suspected polycythemia vera (PV). The testing kit detects mutations in the JAK2 gene in patients with suspected PV by sequencing data [...]
Wed, Apr 26, 2017, Continue reading at the source
The Main purpose of this project to study the uptake pattern of FLT-PET and it is value in assessing the malignant hematopoiesis in MPN within the pediatric age group, in terms of diagnosis, staging and monitoring response to therapy. As well as, evaluating FLT-PET as a novel non-invasive technique in [...]
Wed, Apr 26, 2017, Continue reading at the source
The introduction of the JAK1 and JAK2 inhibitor ruxolitinib has significantly improved outcomes for some patients with myeloproliferative neoplasms (MPNs); however, the therapeutic armamentarium is still largely inadequate, researchers at the University of Florence, Italy, report in a study published in Blood. [...]
Wed, Apr 26, 2017, Continue reading at the source
While clinical trials are paving the way for new treatments to treat hematologic malignancies, but many patients are apprehensive to participate in them after considering the costs. Clinical trials are leading the way in developing new treatments for hematologic malignancies, but the cost associated with them may be holding many patients [...]
Tue, Apr 25, 2017, Continue reading at the source
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea. Read more [...]
Tue, Apr 25, 2017, Continue reading at the source
Annual Hematology Meeting Updates: CML and MPN
A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining to the care of patients with chronic myelogenous leukemia (CML) and myeloproliferative neoplasms (MPN) in this Best of the Day discussion from [...]
Sun, Jan 29, 2017, Continue reading at the source
Long Term Exposure to Radiation puts you at higher risk for MPN A Savannah River Site Worker The Savannah River Site is on a list of qualified places for Special Exposure Cohort Employees (SEC) The SEC allows eligible claimants to be compensated without the completion of a NIOSH radiation dose reconstruction or determination [...]
Mon, Jan 02, 2017, Continue reading at the source
A survey is being conducted to learn more about the most common symptoms experienced by ET patients, and how these symptoms affect the lives of patients. This information may help improve how the patient's experience is accounted for in clinical trials that measure the effect of treatments. The study is [...]
Wed, Dec 21, 2016, Continue reading at the source
Leukemia cure could be on the way, says med-tech firm Biosight
New Leukemia Research in Phase I/IIa Clinical Trial Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an investment of $13 million led by pharmaceutical investment firm Arkin Holdings, run by pharma mogul Mori Arkin, and US-based venture firm Primera Capital. The money [...]
Tue, Oct 18, 2016, Continue reading at the source
For anyone who lives a fast-paced life, it is easy to sometimes forget our need to take care of ourselves and to listen to our bodies. It is easy to get distracted from the importance of a healthy lifestyle when it seems there is so much to be done. But it [...]
Tue, Mar 15, 2016, Continue reading at the source
February 29th is Rare Disease Day: 4 Reasons You Should Care Even though MPN patients who have a rare disease many may have never heard of "Rare Disease Day" and know next to nothing about the impact rare disorders have on society. Rare diseases play a larger role in public [...]
Mon, Feb 29, 2016, Continue reading at the source
It's World Cancer Day There has been, from time to time, a question about whether myeloproliferative neoplasms are cancers. Let's be clear, they are. But don't take our word for it. Cancer Support Community defines Myeloproliferative Neoplasms (MPNs) as types of blood cancers that overproduce blood cells in the bone [...]
Mon, Feb 01, 2016, Continue reading at the source
For the past several months we've kept you informed and taking action on Medicare's pending decision of whether to provide coverage for people with myelofibrosis seeking a stem cell transplant. Currently there is no official ruling from Medicare on whether this treatment is covered, leaving many patients to risk paying [...]
Tue, Jan 12, 2016, Continue reading at the source
Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award. The two categories are commitment to the community or individual. Past winners have included Ruben Mesa, Zhenya Senyak, Joyce Niblack, Richard Silver, and many more. We [...]
Sun, Dec 27, 2015, Continue reading at the source
According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, "This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in [...]
Tue, Dec 01, 2015, Continue reading at the source


Check out more resources at MPN Cancer Connection!Click here
error: Content is protected !!